The entire pharmaceutical industry facing uncertain times in 2005. Many of the industry’s most pressing issues – patent expirations, new drug development pipeline, pricing pressures, regulatory issues and political pressure – had long since. Fundamentally new technologies are changing the way drugs were discovered were developed and tested to give so that smaller, specialized competitors in the industry to compete in new ways, and to grow, to challenge the majors. Some observers were even questioning w … Read more »

The entire pharmaceutical industry facing uncertain times in 2005. Many of the industry’s most pressing issues – patent expirations, new drug development pipeline, pricing pressures, regulatory issues and political pressure – had long since. Fundamentally new technologies are changing the way drugs were discovered were developed and tested to give so that smaller, specialized competitors in the industry to compete in new ways, and to grow, to challenge the majors. Some observers even questioned whether the blockbuster model, based on the industry could be continued. Blockbuster drugs with annual sales of more than $ 1 billion per year, were increasingly difficult and costly to develop. The leaders in the industry have been reflected in this context, and with stock prices reflect on their strategies.
A rewritten version of an earlier case.
«Hide

from
John R. Wells,
Elizabeth A. Raabe
Source: Harvard Business School
21 pages.
Publication Date: Oct 27, 2005. Prod #: 706 423 PDF-ENG
Pharmaceutical industry in 2005 HBR case solution

[related_post themes="flat"]